Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Genetic predisposition to adverse consequences of anti–cholinesterases in ‘atypical’ BCHE carriers

Nature Medicine volume 1, pages 1082–1085 (1995)Cite this article

Abstract

Normal butyrylcholinesterase (BuChE)1, but not several of its common genetic variants2, serves as a scavenger for certain anti–cholinesterases (anti–ChEs). Consideration of this phenomenon becomes urgent in view of the large–scale prophylactic use of the anti–ChE, pyridostigmine, during the 1991 Persian Gulf War, in anticipation of nerve gas attack3 and of the anti–ChE, tacrine, for improving residual cholinergic neurotransmission in Alzheimer's disease patients4. Adverse symptoms were reported for subjects in both groups, but have not been attributed to specific causes4,5. Here, we report on an Israeli soldier, homozygous for ‘atypical’ BuChE, who suffered severe symptoms following pyridostigmine prophylaxis during the Persian Gulf War. His serum BuChE and recombinant ‘atypical’ BuChE (ref. 6) were far less sensitive than normal BuChE to inhibition by pyridostigmine and several other carbamate anti–ChEs. Moreover, atypical BuChE demonstrated 1/200th the affinity for tacrine of normal BuChE or the related enzyme acetylcholinesterase (AChE). Genetic differences among BuChE variants may thus explain at least some of the adverse responses to anti–ChE therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Schwarz, M., Click, D., Loewenstein, Y. & Soreq, H. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol Ther. (in the press).

  2. La Du, B.N. et al. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin. Biochem. 23, 423–431 (1990).

    Article  CAS  Google Scholar 

  3. Keeler, J.R., Hurst, C.G. & Dunn, M.A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 266, 693–695 (1991).

    Article  CAS  Google Scholar 

  4. Winker, M.A. Tacrine for Alzheimer's disease; which patient, what dose? JAMA 271, 1023–1024 (1994).

    Article  CAS  Google Scholar 

  5. Sharabi, Y. et al. Survey of symptoms following intake of pyridostigmine during the Persian Gulf War. Isr. J. med. Scl 27, 656–658 (1991).

    CAS  Google Scholar 

  6. Neville, L.F. et al Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE. EMBO J. 11, 1641–1649 (1992).

    Article  CAS  Google Scholar 

  7. McGuire, M.C. et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. natn. Acad. Sci. U.S.A. 86, 953–957 (1989).

    Article  CAS  Google Scholar 

  8. Kalow, W. & Davis, R.O. The activity of various esterase inhibitors towards atypical human serum cholinesterase. Biochem. Pharmacol. 1, 183–192 (1958).

    Article  Google Scholar 

  9. Lockridge, O. Genetic variants of serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol. Ther. 47, 35–60 (1990).

    Article  CAS  Google Scholar 

  10. Ehrlich, G. et al. Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from Transcaucasian Georgia and from Europe. Genomics 22, 288–295 (1994).

    Article  CAS  Google Scholar 

  11. Soreq, H. & Zakut, H. Human Cholinesterases and Anticholinesterases (Academic Press, San Diego, California, 1993).

    Google Scholar 

  12. Schwarz, M. et al. Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. Molec. Brain Res. 31, 101–110 (1995).

    Article  CAS  Google Scholar 

  13. Seidman, S. et al. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3′-terminal exons. Molec. cell. Biol. 15, 2993–3002 (1995).

    Article  CAS  Google Scholar 

  14. Chatonnet, A. & Lockridge, O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260, 625–634 (1989).

    Article  CAS  Google Scholar 

  15. Giacobini, E. The second generation of cholinesterase inhibitors: Pharmacological aspects. in Cholinergic Basis for Alzheimer Therapy (eds Becker, R. & Giacobini, E.) 247–262 (Birkhauser, Boston, 1991).

    Chapter  Google Scholar 

  16. Iversen, L.L. Approaches to cholinergic therapy in Alzheimer's disease. Prog. Brain. Res. 98, 423–426 (1993).

    Article  CAS  Google Scholar 

  17. Enz, A., Amstutz, R., Boddeke, H., Gmelin, G. & Malonowski, J. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog. Brain Res. 98, 431–437 (1993).

    Article  CAS  Google Scholar 

  18. Harel, M. et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. natn. Acad. Sci. U.S.A. 90, 9031–9035 (1993).

    Article  CAS  Google Scholar 

  19. Harel, M. et al. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc. natn. Acad. Sci. U.S.A. 89, 10827–10831 (1992).

    Article  CAS  Google Scholar 

  20. Valentine, R.J., Lockridge, O., Eckerson, H.W. & La Du, B.N. Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies. Biochem. Pharmacol. 30, 1643–1649 (1981).

    Article  Google Scholar 

  21. Gavageran, H. NIH panel rejects Persian Gulf syndrome. Nature 369, 8 (1994).

    Article  Google Scholar 

  22. Ott, P., Lustig, A., Brodbeck, U. & Rosenbusch, J.P. Acetylcholinesterase from human erythrocyte membranes: Dimers as functional units. FEBS Lett. 138, 187–189 (1982).

    Article  CAS  Google Scholar 

  23. Johansson, I.M. & Nordberg, A. Pharmacokinetic studies of cholinesterase inhibitors. Acta neurol. scand. Suppl. 149, 22–25 (1993).

    CAS  PubMed  Google Scholar 

  24. Berman, H.A. & Leonard, K. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. Molec. Pharmacol. 41, 412–418 (1992).

    CAS  Google Scholar 

  25. May, D.G. Genetic differences in drug disposition. J. clin. Pharmacol. 34, 881–897 (1994).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Yael Loewenstein-Lichtenstein

    Present address: Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, California, 94143-0534, USA

Authors and Affiliations

  1. Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University of Jerusalem, 91904, Israel

    Yael Loewenstein-Lichtenstein, Mikael Schwarz, David Glick & Hermona Soreq

  2. Department of Clinical Biochemistry, Statens Serum Institut, Division of Biotechnology, DK-2300, Copenhagen S, Denmark

    Bent Nørgaard-Pedersen

  3. Department of Obstetrics and Gynecology, The Sackler Faculty of Medicine of Tel Aviv University and The Edith Wolfson Medical Center, Holon, 58100, Israel

    Haim Zakut

Authors
  1. Yael Loewenstein-Lichtenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mikael Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Glick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bent Nørgaard-Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haim Zakut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hermona Soreq
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loewenstein-Lichtenstein, Y., Schwarz, M., Glick, D. et al. Genetic predisposition to adverse consequences of anti–cholinesterases in ‘atypical’ BCHE carriers. Nat Med 1, 1082–1085 (1995). https://doi.org/10.1038/nm1095-1082

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1095-1082

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing